<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178902</url>
  </required_header>
  <id_info>
    <org_study_id>M19-025</org_study_id>
    <secondary_id>2018-003744-24</secondary_id>
    <nct_id>NCT04178902</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A First In Human Study of the MCL-1 Inhibitor, ABBV-467</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult
      participants with relapsed/refractory multiple myeloma (MM).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to approximately 24 months after first dose of study drug</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Up to approximately Day 197</time_frame>
    <description>Maximum Serum Concentration (Cmax) of ABBV-467.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2)</measure>
    <time_frame>Up to approximately Day 197</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of ABBV-467</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUCt)</measure>
    <time_frame>Up to approximately Day 197</time_frame>
    <description>AUC from time 0 to time of last measureable concentration of ABBV-467.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC0-∞)</measure>
    <time_frame>Up to approximately Day 197</time_frame>
    <description>AUC from time 0 to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of ABBV-467</measure>
    <time_frame>Up to approximately Day 197</time_frame>
    <description>Clearance of ABBV-467.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 24 months after first dose of study drug</time_frame>
    <description>ORR evaluated per adapted International Myeloma Working Group (IMWG) criteria and defined as partial remission (PR) + very good partial response (VGPR) + complete remission (CR) + stringent complete response (sCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to approximately 24 months after first dose of study drug</time_frame>
    <description>CBR evaluated per adapted International Myeloma Working Group (IMWG) criteria and is defined as minimal response (MR) + PR + VGPR + CR + sCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 24 months after first dose of study drug</time_frame>
    <description>DOR is defined as the time between date of first response and the first occurrence of progression or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Multiple Myeloma (MM)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: ABBV-467 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended Part B dose is determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: ABBV-467 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-467 administered by intravenous (IV) infusion at multiple dose levels and/or schedules as identified in Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-467</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Part A: ABBV-467 Dose Escalation</arm_group_label>
    <arm_group_label>Part B: ABBV-467 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of multiple myeloma (MM)

          -  Measurable disease defined as at least 1 of the following: serum monoclonal protein ≥
             1g/dL or urine M-protein ≥ 200mg/24 hours

          -  Relapsed after or are refractory or intolerant to all established MM therapies that
             are known to provide clinical benefit and locally available

          -  Received at least 3 prior lines of therapy including 1 or more immunomodulatory
             agents, 1 or more proteasome inhibitors, and 1 or more anti-CD38 monoclonal antibodies

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Adequate hematologic, renal and hepatic function

          -  Echocardiogram with ejection fraction ≥ 50% and no other clinically significant
             findings that would increase the participant's susceptibility to cardiac toxicity

        Exclusion Criteria:

          -  Prior exposure to any targeted MCL-1 inhibitor

          -  Antineoplastic therapy (including any cytotoxic, targeted and/or investigational
             therapy; but not including corticosteroids), within 28 days or 5 half-lives, whichever
             is shorter, prior to the first dose of study drug and through the last dose of study
             drug

          -  Autologous stem cell transplant within 90 days prior to start of study drug

          -  Allogenic stem cell transplant within 180 days prior to start of study drug

          -  History of acute or chronic pancreatitis

          -  Significant unresolved liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope /ID# 209786</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center - LaJolla /ID# 210075</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute /ID# 215418</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903-4923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital /ID# 214665</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor /ID# 214588</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hotel Dieu -HME /ID# 215480</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 214065</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital /ID# 214696</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 214697</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 214801</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitar de Navarra - Pamplona /ID# 217170</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra, Comunidad</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron /ID# 214690</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 214672</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Uni Virgen de la Victoria /ID# 214756</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hosp /ID# 209323</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univ Hosp /ID# 209322</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma (MM)</keyword>
  <keyword>Relapse/Refractory</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

